ECDC is following reports from several European Union and European Economic Area (EU/EEA) countries of substantial increases in the detection of parvovirus B19 (B19V).
This protocol describes a survey undertaken to acquire a snapshot of the distribution of Clostridioides difficile strains in tertiary acute care hospitals in the European Union/European Economic Area (EU/EEA) in 2022–2023
A prolonged genomic cluster of 20 human Listeria monocytogenes ST1607 infections has been reported. The most recent case was reported in March 2024 in Denmark.
This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses (compared to complete primary vaccination with no booster) against hospitalisation due to COVID-19 and COVID-19-related death in resident populations ≥50 years of age living in the community.
A cross-border outbreak of Salmonella Mbandaka ST413 has been ongoing in the European Union/European Economic Area (EU/EEA) and the United Kingdom (UK) for over two years since September 2021.
The purpose of this scoping review is to describe and summarise the rationale behind and methodological approaches used to conduct cascade-of-care analyses for TB infection in low-TB incidence countries.
This guidance outlines key strategic and operational considerations to inform pandemic preparedness planning round the design and implementation of public health and social measures in community settings in the EU/EEA.
At the request of the Slovenian National Institute of Public Health (NIJZ), ECDC designed and facilitated an After-Action review (AAR), focusing on the response to the COVID-19 pandemic.
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
This protocol describes the common methodology to be applied to established health data registries across seven participating EU/EEA Member States to estimate vaccine effectiveness for Coronavirus disease 2019 (COVID-19) in children and adolescents aged 5-17 years old.